Good post. I was just pointing out that the Reach trial mentioned is not a particularly good comparison. Best bet would be to look at the Magic Consortium data . These contain very large N values.
In regards to MSC - FFM I came to a conclusion that this approach would go a long way to standardising the product for commercial use but it would be better for research to stay with the individual donor, that way you can do comparison studies between batches.
Good luck.
- Forums
- ASX - By Stock
- Ann: Further GvHD Clinical Data Published in Nature Medicine
Good post. I was just pointing out that the Reach trial...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CYP (ASX) to my watchlist
|
|||||
Last
19.0¢ |
Change
0.010(5.56%) |
Mkt cap ! $34.32M |
Open | High | Low | Value | Volume |
18.0¢ | 19.5¢ | 18.0¢ | $9.062K | 48.88K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 104632 | 18.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
19.0¢ | 3 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4632 | 0.185 |
4 | 66488 | 0.180 |
1 | 285 | 0.175 |
2 | 4148 | 0.170 |
2 | 25050 | 0.165 |
Price($) | Vol. | No. |
---|---|---|
0.190 | 3 | 1 |
0.195 | 38853 | 1 |
0.200 | 25789 | 2 |
0.210 | 60000 | 1 |
0.250 | 16097 | 2 |
Last trade - 14.37pm 12/09/2024 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |